Claims
- 1. Compound represented by the formula: wherein A is selected from the group consisting of W is NH2 or H; each X, Y and Z is independently selected from the group consisting of H, OH and halogen provided that at least one of X and Y is H; W is H or NH2; a tautomer or a pharmaceutically acceptable salt thereof.
- 2. A pharmaceutical composition comprising at least one compound of claim 1 and a pharmaceutically acceptable carrier.
- 3. A method for suppressing purine nucleoside phosphorylase in a patient by administering to the patient in need thereof at least one compound of claim 1 in an amount sufficient to suppress purine nucleoside phosphorylase.
- 4. A method of inhibiting T-cell proliferation in a patient which comprises administering to the patient in need thereof at least one compound of claim 1 in an amount sufficient for inhibiting T-cell proliferation.
- 5. Compound of claim 1 represented by the formula a tautomer, or a pharmaceutically acceptable salt thereof.
CROSS REFERENCES TO RELATED APPLICATION
The present application claims priority under 35 USC 119(e) from U.S. Provisional Application No. 60/191,091 filed Mar. 22, 2000, and entitled “Imminoribitol PNP Inhibitors, Preparation Thereof and Use Thereof.”
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5985848 |
Furneaux |
Nov 1999 |
A |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/191091 |
Mar 2000 |
US |